Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism.
Aged
Brain Mapping
/ methods
Diagnosis, Differential
Diffusion Magnetic Resonance Imaging
Female
Globus Pallidus
/ diagnostic imaging
Humans
Iron
/ metabolism
Male
Middle Aged
Multiple System Atrophy
/ diagnosis
Parkinson Disease
/ diagnosis
Prospective Studies
Putamen
/ diagnostic imaging
Substantia Nigra
/ diagnostic imaging
Supranuclear Palsy, Progressive
/ diagnosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 04 2019
15 04 2019
Historique:
received:
23
11
2018
accepted:
02
04
2019
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
21
10
2020
Statut:
epublish
Résumé
There is a need for methods that distinguish Parkinson's disease (PD) from progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), which have similar characteristics in the early stages of the disease. In this prospective study, we evaluate mapping of apparent susceptibility based on susceptibility weighted imaging (SWI) for differential diagnosis. We included 134 patients with PD, 11 with PSP, 10 with MSA and 44 healthy controls. SWI data were processed into maps of apparent susceptibility. In PSP, apparent susceptibility was increased in the red nucleus compared to all other groups, and in globus pallidus, putamen, substantia nigra and the dentate nucleus compared to PD and controls. In MSA, putaminal susceptibility was increased compared to PD and controls. Including all studied regions and using discriminant analysis between PSP and PD, 100% sensitivity and 97% specificity was achieved, and 91% sensitivity and 90% specificity in separating PSP from MSA. Correlations between putaminal susceptibility and disease severity in PD could warrant further research into using susceptibility mapping for monitoring disease progression and in clinical trials. Our study indicates that susceptibility in deep nuclei could play a role in the diagnosis of atypical parkinsonism, especially in PSP.
Identifiants
pubmed: 30988382
doi: 10.1038/s41598-019-42565-4
pii: 10.1038/s41598-019-42565-4
pmc: PMC6465307
doi:
Substances chimiques
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6079Références
Clin Imaging. 2017 Jul - Aug;44:66-69
pubmed: 28460362
Mov Disord. 2017 Apr;32(4):619-623
pubmed: 28151553
Neuroradiology. 2015 Nov;57(11):1079-91
pubmed: 26253801
AJNR Am J Neuroradiol. 2015 Mar;36(3):454-60
pubmed: 25339647
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
NMR Biomed. 2014 Feb;27(2):219-27
pubmed: 24357120
Neuroimage. 2011 Jun 1;56(3):907-22
pubmed: 21352927
Magn Reson Imaging. 2015 Jun;33(5):559-65
pubmed: 25721997
Parkinsonism Relat Disord. 2017 Nov;44:51-57
pubmed: 28886909
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Mov Disord. 2015 Jul;30(8):1068-76
pubmed: 25773707
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Neuropathol Appl Neurobiol. 2012 Feb;38(1):4-24
pubmed: 22074330
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Eur Radiol. 2013 Jan;23(1):12-9
pubmed: 22797981
Arch Neurol. 1999 Jan;56(1):33-9
pubmed: 9923759
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S82-92
pubmed: 26421389
Magn Reson Med. 2012 Jan;67(1):137-47
pubmed: 21671269
J Neural Transm (Vienna). 2017 Aug;124(8):915-964
pubmed: 28378231
Neurology. 2015 Aug 4;85(5):404-12
pubmed: 26138942
Neuroimage. 2015 Mar;108:111-22
pubmed: 25536496
Transl Neurodegener. 2016 Oct 7;5:17
pubmed: 27761236
AJNR Am J Neuroradiol. 2015 Jun;36(6):1102-8
pubmed: 25767187
Mov Disord. 2017 Jul;32(7):955-971
pubmed: 28500751
Hum Brain Mapp. 2002 Nov;17(3):143-55
pubmed: 12391568
Neuroimage. 2011 Apr 15;55(4):1645-56
pubmed: 21224002
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Acta Neuropathol. 2003 Aug;106(2):143-9
pubmed: 12732936
Lancet Neurol. 2009 Mar;8(3):270-9
pubmed: 19233037
Radiographics. 2014 Sep-Oct;34(5):1273-92
pubmed: 25208280
Neuroimage. 2002 Oct;17(2):825-41
pubmed: 12377157
Neurology. 2015 Jan 6;84(1):57-63
pubmed: 25411441
Mov Disord. 2016 May;31(5):684-92
pubmed: 26990970
Neuroimage. 2012 Sep;62(3):1593-9
pubmed: 22634862
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Lancet Neurol. 2004 Feb;3(2):93-103
pubmed: 14747001
J Neurol Sci. 2016 Sep 15;368:104-8
pubmed: 27538610